L-Ornithine-L-Aspartate
Release time:2021-12-12
Indications:
For the treatment of hyperammonemia as a result of acute and chronic
liver diseases such as liver cirrhosis, fatty liver,
hepatitis; especially for the treatment of incipient disturbances of
consciousness (pre-coma) or neurological complications (hepatic
encephalopathy).
Reprint statement: reprint please indicate "source: Wista pharma".
Back
Nitrofurantoin

简体中文



86-10-67887855
Head Office:
Marketing:
Wista Pharmam